while the 36-month beta value is 1.12.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”

The average price point forecasted by analysts for ImmunityBio Inc (IBRX) is $4.00, which is -$0.14 below the current market price. The public float for IBRX is 130.77M, and currently, short sellers hold a 32.06% ratio of that floaft. The average trading volume of IBRX on November 20, 2023 was 5.15M shares.

Elon Musk just Triggered a BOOM in These Stocks

Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"

Click Here to Download the FREE Report.


IBRX) stock’s latest price update

ImmunityBio Inc (NASDAQ: IBRX)’s stock price has soared by 1.22 in relation to previous closing price of 4.09. Nevertheless, the company has seen a gain of 33.12% in its stock price over the last five trading days. InvestorPlace reported 2023-11-06 that Biotech stocks are incredibly risky but can provide investors with huge returns since insurers in the U.S. will pay tremendous amounts for successful treatments. In the last few months in particular, the potential risks of biotech stocks have increased only a bit while their possible returns have increased tremendously.

IBRX’s Market Performance

IBRX’s stock has risen by 33.12% in the past week, with a monthly rise of 229.88% and a quarterly rise of 151.67%. The volatility ratio for the week is 12.00% while the volatility levels for the last 30 days are 19.01% for ImmunityBio Inc. The simple moving average for the past 20 days is 39.34% for IBRX’s stock, with a 71.96% simple moving average for the past 200 days.

Analysts’ Opinion of IBRX

Many brokerage firms have already submitted their reports for IBRX stocks, with Piper Sandler repeating the rating for IBRX by listing it as a “Neutral.” The predicted price for IBRX in the upcoming period, according to Piper Sandler is $4 based on the research report published on May 12, 2023 of the current year 2023.

IBRX Trading at 97.11% from the 50-Day Moving Average

After a stumble in the market that brought IBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.69% of loss for the given period.

Volatility was left at 19.01%, however, over the last 30 days, the volatility rate increased by 12.00%, as shares surge +218.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +220.93% upper at present.

During the last 5 trading sessions, IBRX rose by +33.12%, which changed the moving average for the period of 200-days by -6.97% in comparison to the 20-day moving average, which settled at $3.11. In addition, ImmunityBio Inc saw -18.34% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at IBRX starting from BLASZYK MICHAEL D, who purchase 71,915 shares at the price of $2.75 back on Jun 05. After this action, BLASZYK MICHAEL D now owns 71,915 shares of ImmunityBio Inc, valued at $198,023 using the latest closing price.

Brennan John Owen, the Director of ImmunityBio Inc, purchase 25,000 shares at $2.83 during a trade that took place back on Jun 02, which means that Brennan John Owen is holding 25,000 shares at $70,700 based on the most recent closing price.

Stock Fundamentals for IBRX

Current profitability levels for the company are sitting at:

The net margin for ImmunityBio Inc stands at -173569.58.

When we switch over and look at the enterprise to sales, we see a ratio of 6,083.54, with the company’s debt to enterprise value settled at 0.27. The receivables turnover for the company is 0.15 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.28.


In a nutshell, ImmunityBio Inc (IBRX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.